The P-NPNT research area falls under the broad discipline of chemical biology. There is a strong focus on molecular pharmacology, pharmaceutics and application of a variety of high-end bioanalytical techniques such as LC-MS/MS, GC-MS/MS, nanoflow proteomics, NMR, and IR and Raman Spectroscopy.
The Pharmacy Natural Products and Novel Therapeutics (P-NPNT) group is part of a larger multidisciplinary research group (NPNT) that spans the Faculty of Health and the University. Research within Pharmacy focuses on novel therapeutic agents derived from (primarily) plant sources as well as novel applications of existing drugs and formulations (drug re-profiling).
The P-NPNT has its own zebrafish facility which is being used for a number of research projects including cardiac muscle physiology, development of novel muscle and cardiac assays, as well as anticancer applications utilising an angiogenesis model and microinjection xenotransplant tumour model.
The P-NPNT undertakes a variety of projects, from custom method development analytical techniques for pharmacokinetic applications through to utilising routine screening assays, with both academic collaborators and fee for service industry clients. The P-NPNT group works closely with the Central Sciences Laboratory at the University of Tasmania.
Screening capability includes antibacterial and antifungal activity (disk diffusion and MIC), antioxidant activity (FRAPP, DPPH and beta-carotene; serum peroxidation), oxidative stress (plasma malondialdehyde; plasma glutathione peroxidase levels (GSH-Px) and activity, plasma selenium), cytotoxicity/anticancer (brine shrimp, PBMC, P388 murine leukaemia).
Authorised by the Associate Head, Pharmacy
10 April, 2015